Skip to main content
SpringerLink
Log in
Birkhäuser

Glutamate-based Therapies for Psychiatric Disorders

  • Book
  • © 2010

Overview

Editors:
  1. Phil Skolnick

    1. Div Pharmacotherapies & Medical Conseque, National Institute on Drug Abuse, Rockville, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • Contemporary monograph on glutamate-based approaches to treat psychiatric drugs
  • The approaches described in this text exploit both metabotropic and ionotropic glutamate receptors Focus on translational research, with many of the authors coming from industry All are acknowledged authorities in the glutamate field
  • Includes supplementary material: sn.pub/extras

Part of the book series: Milestones in Drug Therapy (MDT)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (9 chapters)

  1. Front Matter

    Pages i-xiv
    Download chapter PDF

  2. N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression

    • Phil Skolnick, Piotr Popik, Ramon Trullas
    Pages 1-20

  3. Ionic Glutamate Modulators in Depression (Zinc, Magnesium)

    • Bernadeta Szewczyk, Ewa Poleszak, Andrzej Pilc, Gabriel Nowak
    Pages 21-38

  4. Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy

    • Eric S. Nisenbaum, Jeffrey M. Witkin
    Pages 39-56

  5. Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors

    • Jeffrey M. Witkin
    Pages 57-74

  6. Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders

    • Gary Lynch, Julie C. Lauterborn, Christine M. Gall
    Pages 75-100

  7. Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia

    • Douglas J. Sheffler, P. Jeffrey Conn
    Pages 101-116

  8. mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia

    • Hisashi Ohta, Hiroshi Kawamoto, Gentaroh Suzuki
    Pages 117-131

  9. Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence

    • Svetlana Semenova, Athina Markou
    Pages 133-156

  10. Metabotropic Approaches to Anxiety

    • Joanna M. Wieronska, Gabriel Nowak, Andrzej Pilc
    Pages 157-173

  11. Back Matter

    Pages 175-178
    Download chapter PDF
Back to top

Keywords

About this book

Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the treatment of psychiatric disorders. This “Milestones in Drug Therapy” volume offers a unique, contemporary overview of preclinical and clinical evidence that modulating glutamatergic tone is an effective means of treating psychiatric disorders ranging from depression and anxiety to schizophrenia and drug abuse. The ability to treat diseases such as depression and schizophrenia through multiple, glutamate-based mechanisms offers a unique therapeutic opportunity, as described in this book.

Reviews

From the reviews:

“This book summarizes the translational research in the development of glutamate-based approaches to treat psychiatric disorders. Written and edited by an international group of researchers, it is an important addition to the psychiatric literature. … The intended audience includes psychiatric researchers and psychiatrists. Neuroscientists interested in the treatment of patients with psychiatric disorders also would benefit from reading this book. … The index is quite helpful. … presents a unique and novel approach that is desperately needed in the treatment of these difficult disorders.” (Michael Joel Schrift, Doody’s Review Service, February, 2011)

Editors and Affiliations

  • Div Pharmacotherapies & Medical Conseque, National Institute on Drug Abuse, Rockville, USA

    Phil Skolnick

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation